Clinical Trials Browser

Phase 1 × atezolizumab × Plasma cell × Clear all

NCT04045028 2023-04-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell

NCT02431208 2021-04-02

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Phase 1 Completed

Multiple Myeloma

NCT02784483 2020-03-03

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Phase 1 Terminated

Smoldering Multiple Myeloma